Your browser is no longer supported. Please, upgrade your browser.
PTGX Protagonist Therapeutics, Inc. daily Stock Chart
Protagonist Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.15 Insider Own1.30% Shs Outstand27.70M Perf Week-8.23%
Market Cap602.24M Forward P/E- EPS next Y-2.31 Insider Trans2.56% Shs Float21.19M Perf Month0.56%
Income-83.20M PEG- EPS next Q-0.69 Inst Own83.30% Short Float6.21% Perf Quarter134.39%
Sales2.30M P/S261.84 EPS this Y-71.30% Inst Trans6.27% Short Ratio1.18 Perf Half Y132.05%
Book/sh2.26 P/B7.21 EPS next Y20.00% ROA-56.10% Target Price27.50 Perf Year19.34%
Cash/sh3.18 P/C5.13 EPS next 5Y- ROE-103.20% 52W Range4.47 - 19.67 Perf YTD131.06%
Dividend- P/FCF- EPS past 5Y-31.30% ROI-88.90% 52W High-17.18% Beta1.38
Dividend %- Quick Ratio3.50 Sales past 5Y- Gross Margin- 52W Low264.43% ATR1.12
Employees80 Current Ratio3.50 Sales Q/Q125.00% Oper. Margin- RSI (14)43.03 Volatility6.04% 6.62%
OptionableYes Debt/Eq0.16 EPS Q/Q-24.90% Profit Margin- Rel Volume0.28 Prev Close17.49
ShortableYes LT Debt/Eq0.16 EarningsMay 07 AMC Payout- Avg Volume1.11M Price16.29
Recom1.60 SMA20-6.51% SMA505.75% SMA20057.63% Volume312,067 Change-6.86%
May-18-20Reiterated H.C. Wainwright Buy $23 → $28
Jul-08-19Initiated H.C. Wainwright Buy $23
May-09-19Upgrade Stifel Hold → Buy $11 → $17
Dec-06-18Initiated Nomura Buy $13
Jan-29-18Initiated Stifel Buy $32
Jul-21-17Initiated BTIG Research Buy $36
Jun-27-20 09:27PM  
Jun-18-20 10:23AM  
Jun-17-20 11:07PM  
Jun-16-20 06:05PM  
Jun-15-20 07:06PM  
Jun-04-20 07:00AM  
May-28-20 07:00AM  
May-18-20 07:32AM  
May-12-20 12:57AM  
May-11-20 09:52AM  
May-10-20 07:30AM  
May-08-20 05:23PM  
May-07-20 04:31PM  
May-01-20 12:11PM  
Apr-21-20 10:35AM  
Apr-15-20 08:35PM  
Mar-28-20 11:42AM  
Mar-13-20 11:40AM  
Mar-10-20 05:45PM  
Mar-03-20 12:30PM  
Mar-02-20 04:30PM  
Feb-19-20 07:00AM  
Feb-11-20 11:18AM  
Feb-07-20 07:00AM  
Jan-07-20 09:59AM  
Jan-06-20 07:00AM  
Dec-12-19 06:00PM  
Dec-11-19 06:37AM  
Dec-04-19 07:06AM  
Dec-03-19 07:00AM  
Nov-13-19 07:00AM  
Nov-06-19 07:55PM  
Oct-31-19 07:00AM  
Oct-29-19 10:32AM  
Oct-22-19 07:51AM  
Oct-20-19 08:08AM  
Oct-02-19 11:39AM  
Oct-01-19 07:00AM  
Sep-25-19 07:00AM  
Sep-04-19 04:30PM  
Sep-03-19 04:30PM  
Aug-27-19 11:51AM  
Aug-07-19 08:35AM  
Aug-01-19 04:30PM  
Jul-30-19 10:38AM  
Jul-16-19 04:05PM  
Jul-11-19 03:36PM  
Jun-23-19 04:11PM  
Jun-18-19 04:30PM  
Jun-17-19 07:00AM  
Jun-04-19 07:00AM  
May-29-19 04:30PM  
May-15-19 06:23PM  
May-14-19 07:00AM  
May-08-19 08:35AM  
May-07-19 07:00AM  
May-01-19 10:32AM  
Apr-01-19 07:00AM  
Mar-18-19 11:12AM  
Mar-12-19 04:25PM  
Mar-05-19 07:00AM  
Feb-21-19 07:00AM  
Feb-05-19 08:10AM  
Jan-16-19 04:30PM  
Jan-09-19 07:00AM  
Dec-24-18 09:53AM  
Dec-20-18 10:42AM  
Dec-13-18 07:00AM  
Dec-05-18 07:00AM  
Nov-29-18 08:09AM  
Nov-27-18 04:01PM  
Nov-09-18 08:40AM  
Nov-07-18 04:30PM  
Nov-06-18 08:05PM  
Oct-29-18 10:31AM  
Oct-22-18 08:31AM  
Oct-10-18 07:35AM  
Oct-08-18 07:13AM  
Sep-27-18 07:00AM  
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat patients with moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating inflammatory bowel disease. It is also involved in researching oral and injectable peptide-based product candidates for a range of conditions, including gastrointestinal diseases. The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis. Protagonist Therapeutics, Inc. was founded in 2006 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PATEL DINESH V PH DPresident and CEOMar 20Option Exercise1.8910,00018,900439,990Mar 23 06:14 PM
PATEL DINESH V PH DPresident and CEOMar 12Option Exercise1.1618,34421,279429,990Mar 13 01:04 PM
SELICK HAROLD EDirectorMar 12Buy6.7012,00080,40015,310Mar 12 07:26 PM
Giraudo BryanDirectorDec 03Buy5.708,00045,6208,000Dec 03 06:46 PM
Gupta SuneelEVP Clinical OperationsDec 03Buy5.1330,000153,90049,500Dec 03 06:32 PM
Kalkofen Donald A.Chief Financial OfficerDec 03Buy5.101,1755,9871,175Dec 03 06:11 PM
PATEL DINESH V PH DPresident and CEODec 03Buy5.6230,000168,500409,824Dec 03 06:10 PM
PATEL DINESH V PH DPresident and CEONov 26Option Exercise1.164,0004,640379,824Nov 27 02:58 PM
Liu David YChief Scientific OfficerAug 06Sale8.853,39530,04449,802Aug 08 06:17 PM
PATEL DINESH V PH DPresident and CEOAug 06Sale8.8510,79295,535374,792Aug 08 06:15 PM